Amgen’s DLL3-targeted Imdelltra scores overall survival win in first-line small cell lung cancer

In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival win in first-line small cell lung cancer (SCLC). | While Amgen gave no numerical results from Imdelltra's latest overall survival win in first-line small cell lung cancer, R&D chief Jay Bradner said data suggest the DLL3 bispecific “will further revolutionize the standard for survival earlier in the treatment journey.”